CD274 and head and neck squamous cell carcinoma: Moreover, Pembrolizumab monotherapy is indicated by EMA for first-line treatment of patients with metastatic or unresectable, recurrent HNSCC whose tumors express programmed death ligand 1 (PD-L1- combined positive score (CPS) ≥1).